Bicycle Therapeutics Management
Management criteria checks 4/4
Bicycle Therapeutics' CEO is Kevin Lee, appointed in Sep 2015, has a tenure of 8.83 years. total yearly compensation is $5.54M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $5.95M. The average tenure of the management team and the board of directors is 3.4 years and 5 years respectively.
Key information
Kevin Lee
Chief executive officer
US$5.5m
Total compensation
CEO salary percentage | 12.8% |
CEO tenure | 8.8yrs |
CEO ownership | 0.4% |
Management average tenure | 3.4yrs |
Board average tenure | 5yrs |
Recent management updates
Recent updates
Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates
Mar 08Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Feb 23CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$168m |
Dec 31 2023 | US$6m | US$710k | -US$181m |
Sep 30 2023 | n/a | n/a | -US$162m |
Jun 30 2023 | n/a | n/a | -US$140m |
Mar 31 2023 | n/a | n/a | -US$124m |
Dec 31 2022 | US$9m | US$673k | -US$113m |
Sep 30 2022 | n/a | n/a | -US$101m |
Jun 30 2022 | n/a | n/a | -US$87m |
Mar 31 2022 | n/a | n/a | -US$78m |
Dec 31 2021 | US$4m | US$677k | -US$67m |
Sep 30 2021 | n/a | n/a | -US$66m |
Jun 30 2021 | n/a | n/a | -US$62m |
Mar 31 2021 | n/a | n/a | -US$56m |
Dec 31 2020 | US$3m | US$592k | -US$51m |
Sep 30 2020 | n/a | n/a | -US$38m |
Jun 30 2020 | n/a | n/a | -US$37m |
Mar 31 2020 | n/a | n/a | -US$35m |
Dec 31 2019 | US$4m | US$517k | -US$31m |
Sep 30 2019 | n/a | n/a | -US$33m |
Jun 30 2019 | n/a | n/a | -US$31m |
Mar 31 2019 | n/a | n/a | -US$26m |
Dec 31 2018 | US$818k | US$386k | -US$22m |
Compensation vs Market: Kevin's total compensation ($USD5.54M) is about average for companies of similar size in the US market ($USD5.54M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
CEO
Kevin Lee (56 yo)
8.8yrs
Tenure
US$5,540,400
Compensation
Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Executive Director | 8.8yrs | US$5.54m | 0.37% $ 5.9m | |
Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.9m | |
Chief Financial Officer | less than a year | US$2.88m | no data | |
Chief Development Officer | 1.3yrs | US$2.82m | 0% $ 0 | |
Scientific Founder | no data | no data | no data | |
Chief Operating Officer | 2.5yrs | US$5.98m | 0.023% $ 370.4k | |
Senior VP | 1.1yrs | no data | 0.0033% $ 53.4k | |
Chief Technology Officer | 2.5yrs | US$3.07m | 0.072% $ 1.2m | |
Chief Scientific Officer | 7.5yrs | no data | 0.036% $ 576.6k | |
General Counsel | 4.3yrs | no data | no data | |
Head of Clinical and Project Management | 8.2yrs | no data | no data | |
Senior VP of Pre-Clinical Development | 5.7yrs | no data | no data |
3.4yrs
Average Tenure
56yo
Average Age
Experienced Management: BCYC's management team is considered experienced (3.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Executive Director | 8.8yrs | US$5.54m | 0.37% $ 5.9m | |
Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.9m | |
Chairman of Scientific Advisory Board | 6.2yrs | no data | no data | |
Non-Executive Chairman | 5.3yrs | US$1.06m | 0.031% $ 506.7k | |
Independent Non-Executive Director | 3.3yrs | US$482.29k | 0.016% $ 253.3k | |
Independent Non-Executive Director | 5yrs | US$526.91k | 0.016% $ 253.3k | |
Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
Independent Non-Executive Director | 5yrs | US$495.41k | 0.016% $ 253.3k | |
Member of Scientific Advisory Board | 6.2yrs | no data | no data | |
Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
Member of Scientific Advisory Board | 3.8yrs | no data | no data |
5.0yrs
Average Tenure
64yo
Average Age
Experienced Board: BCYC's board of directors are considered experienced (5 years average tenure).